An alternative treatment strategy which can cross the blood-nerve barrier is warranted.<h4>Case</h4>A 64-year-old woman had a history of <i>MYD88L265P</i> mutated diffuse large B-cell lymphoma (DLBCL) successfully treated with Pola-R-CHP plus high-dose methotrexate one year prior. This evidence concerns the gene POLA1 and diffuse large B-cell lymphoma.